Dec-16-20 Initiated
UBS
Neutral
$13
Nov-12-20 Upgrade
Raymond James
Underperform → Mkt Perform
Jun-26-20 Downgrade
Raymond James
Mkt Perform → Underperform
May-13-20 Initiated
RBC Capital Mkts
Outperform
$24
May-05-20 Upgrade
SunTrust
Hold → Buy
$13 → $21
Apr-28-20 Initiated
Goldman
Buy
$17
Mar-16-20 Initiated
SVB Leerink
Outperform
$17
Feb-10-20 Upgrade
Chardan Capital Markets
Neutral → Buy
$20
Feb-10-20 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$8 → $21
Oct-15-19 Reiterated
Chardan Capital Markets
Neutral
$6 → $10
Sep-13-19 Reiterated
Chardan Capital Markets
Neutral
$10 → $6
Jun-14-19 Resumed
Raymond James
Mkt Perform
Nov-02-18 Downgrade
SunTrust
Buy → Hold
Nov-02-18 Downgrade
Raymond James
Outperform → Mkt Perform
Sep-21-18 Initiated
Cantor Fitzgerald
Overweight
Aug-30-18 Initiated
SunTrust
Buy
$11
Feb-15-18 Resumed
Piper Jaffray
Overweight
$12
Oct-12-17 Initiated
Raymond James
Outperform
$6
Apr-16-21 08:05AM
Apr-15-21 08:00AM
Apr-08-21 09:39AM
Mar-30-21 09:00AM
Mar-18-21 04:00PM
08:16AM
Mar-17-21 05:10PM
Mar-05-21 08:30AM
Mar-02-21 07:31AM
Mar-01-21 05:25PM
04:00PM
02:30PM
Feb-22-21 04:00PM
09:00AM
Feb-18-21 04:00PM
Feb-10-21 04:49PM
Feb-02-21 09:00AM
Jan-21-21 11:02PM
Jan-11-21 12:00PM
08:00AM
Jan-08-21 08:49AM
Jan-07-21 11:57AM
Jan-05-21 09:00AM
Dec-21-20 10:23AM
Dec-14-20 09:00AM
Nov-23-20 11:00AM
Nov-14-20 10:00AM
Nov-08-20 07:32AM
Nov-05-20 06:35PM
04:01PM
Oct-20-20 09:00AM
Oct-09-20 08:56AM
Sep-29-20 05:23PM
Sep-15-20 08:00AM
Sep-10-20 08:00AM
Sep-08-20 08:57AM
Aug-20-20 07:57AM
Aug-18-20 09:00AM
Aug-17-20 08:51AM
Aug-12-20 09:37PM
Aug-11-20 04:01PM
01:30PM
Aug-10-20 05:35PM
04:00PM
Jul-29-20 04:05PM
Jul-21-20 08:00AM
Jul-20-20 11:07AM
Jul-13-20 08:30AM
Jul-06-20 09:00AM
Jun-30-20 11:50PM Thomson Reuters StreetEvents
Jun-25-20 04:01PM
Jun-16-20 08:13AM
Jun-15-20 04:01PM
09:18AM
Jun-04-20 04:05PM
May-29-20 11:30AM
May-28-20 05:45PM
04:01PM
02:30PM
May-25-20 11:30AM
May-21-20 04:05PM
May-09-20 08:00AM
May-07-20 11:30AM
May-06-20 12:53PM
May-05-20 04:11PM Investor's Business Daily +38.35%
10:42AM
08:00AM
May-04-20 05:10PM
08:20AM
May-03-20 07:00AM
Apr-30-20 04:05PM
Apr-28-20 12:00PM
12:00PM
Apr-27-20 04:01PM
08:00AM
Apr-20-20 04:05PM
Apr-01-20 01:42AM Thomson Reuters StreetEvents -10.54%
Mar-26-20 08:55AM
Mar-18-20 12:00PM
Mar-16-20 06:06AM
Mar-12-20 05:55PM
04:01PM
02:30PM
Mar-11-20 04:38PM
09:46AM
Mar-05-20 04:01PM
Mar-04-20 04:25PM
Mar-03-20 02:20PM
10:29AM
Mar-02-20 05:50PM
Feb-26-20 06:50PM
03:00PM
12:30PM
09:30AM
Feb-25-20 03:00PM
12:26PM
10:00AM
08:00AM
Feb-24-20 05:31PM
05:10PM
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fischer Laurent CEO and Director Mar 24 Buy 9.88 10,000 98,780 26,292 Mar 24 07:47 PM Machado Patrick Director Mar 24 Buy 9.92 10,000 99,196 88,182 Mar 24 07:46 PM PATTERSON LEONE D President and CFO Feb 09 Sale 14.10 12,533 176,718 97,955 Feb 11 07:47 PM Machado Patrick Director Jan 15 Buy 11.52 10,000 115,174 78,182 Jan 19 08:33 PM Fischer Laurent CEO and Director Jan 15 Buy 11.53 8,600 99,191 16,292 Jan 19 08:32 PM Soparkar Peter Chief Legal Officer Aug 17 Buy 13.00 7,692 99,996 10,692 Aug 19 06:48 PM Fischer Laurent CEO and Director Aug 17 Buy 13.00 7,692 99,996 7,692 Aug 19 06:45 PM Gasmi Mehdi Director Jul 20 Option Exercise 4.80 5,000 24,000 279,442 Jul 22 09:44 PM Gasmi Mehdi Director Jul 20 Sale 17.60 5,000 87,978 274,442 Jul 22 09:44 PM Gasmi Mehdi Director Jun 22 Option Exercise 4.80 23,605 113,304 298,047 Jun 23 06:58 PM Gasmi Mehdi Director Jun 22 Sale 25.06 23,605 591,617 274,442 Jun 23 06:58 PM Gasmi Mehdi Director Jun 18 Option Exercise 4.80 11,127 53,410 285,569 Jun 18 09:45 PM Gasmi Mehdi Director Jun 18 Sale 25.01 11,127 278,329 274,442 Jun 18 09:45 PM Gasmi Mehdi Director Jun 17 Option Exercise 4.80 268 1,286 274,710 Jun 18 09:45 PM Gasmi Mehdi Director Jun 17 Sale 25.01 268 6,703 274,442 Jun 18 09:45 PM PATTERSON LEONE D President Jun 16 Sale 24.68 13,171 325,060 110,488 Jun 17 05:47 PM Gasmi Mehdi Director Jun 15 Option Exercise 4.80 10,000 48,000 284,442 Jun 17 05:14 PM Gasmi Mehdi Director Jun 15 Sale 21.86 10,000 218,627 274,442 Jun 17 05:14 PM Gasmi Mehdi Director May 21 Option Exercise 4.80 3,599 17,275 278,041 May 22 06:55 PM Gasmi Mehdi Director May 20 Option Exercise 4.80 1,401 6,725 275,843 May 22 06:55 PM Gasmi Mehdi Director May 20 Sale 20.01 1,401 28,030 274,442 May 22 06:55 PM Gasmi Mehdi Director May 18 Option Exercise 4.80 5,000 24,000 279,442 May 20 07:34 PM Gasmi Mehdi Director May 18 Sale 18.17 5,000 90,833 274,442 May 20 07:34 PM Gasmi Mehdi Director May 06 Option Exercise 4.80 25,000 120,000 299,442 May 20 07:34 PM PATTERSON LEONE D CEO, President and Director May 06 Option Exercise 3.44 20,000 68,800 143,659 May 08 06:25 PM Gasmi Mehdi Director May 06 Sale 20.03 25,000 500,668 274,442 May 20 07:34 PM PATTERSON LEONE D CEO, President and Director May 06 Sale 20.02 20,000 400,400 123,659 May 08 06:25 PM Gasmi Mehdi Director May 05 Option Exercise 4.80 10,000 48,000 284,442 May 20 07:34 PM Gasmi Mehdi Director May 05 Sale 16.26 10,000 162,573 274,442 May 20 07:34 PM Scopa James Paul Director May 04 Option Exercise 6.48 23,334 151,204 53,334 May 05 06:44 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite